GO:0006298 mismatch repair: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0006298 mismatch repair (MMR) is a biological process that corrects base-base mismatches and insertion-deletion loops generated during DNA replication and recombination, thereby promoting genomic fidelity.
• The MMR pathway is initiated by MutS homolog (MSH) complexes that recognize mismatches, followed by MutL homolog (MLH/PMS) complexes that coordinate excision and resynthesis.
• Defects in MMR genes cause microsatellite instability (MSI) and are a hallmark of Lynch syndrome and a subset of sporadic cancers.
• MMR deficiency is a predictive biomarker for immune checkpoint inhibitor therapy in solid tumors.
• Beyond cancer, MMR proteins have non-canonical functions in DNA damage response, neurodegeneration, and Huntington's disease.
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) are essential for dissecting MMR gene function and for developing targeted therapies.
Description
Mismatch repair (MMR) is a highly conserved biological process that corrects errors introduced during DNA replication and recombination, thereby maintaining genomic stability. The process is defined by GO:0006298 and involves the recognition of base-base mismatches and insertion-deletion loops, followed by excision of the error-containing strand and resynthesis using the parental strand as a template. MMR is essential for genomic fidelity, and its dysfunction leads to a mutator phenotype characterized by microsatellite instability (MSI) and increased mutation rates. Researchers study MMR to understand cancer predisposition, therapeutic responses, and basic mechanisms of DNA repair. The pathway is also implicated in non-canonical functions, including DNA damage signaling and neurodegeneration. This article provides a comprehensive overview of the MMR process, its key genes, regulatory mechanisms, disease associations, and research methodologies, with a focus on CRISPR-based models for functional studies.
mismatch repair At A Glance
| GO ID | GO:0006298 |
|---|---|
| GO term | mismatch repair |
| Ontology | biological_process |
| Synonym | MMR; MutS/MutL/MutH pathway; long patch mismatch repair system; MutL-like pathway |
| Major function | Correction of base-base mismatches and insertion-deletion loops generated during DNA replication and recombination |
| Key protein families | MutS homologs (MSH2, MSH3, MSH6), MutL homologs (MLH1, PMS2, PMS1, MLH3), and accessory factors (EXO1, PCNA, RPA, DNA polymerase delta) |
| Associated diseases | Lynch syndrome, sporadic cancers with microsatellite instability, Huntington's disease |
| Research relevance | Biomarker for immunotherapy response; target for cancer therapy; model for DNA repair mechanisms |
What Is GO:0006298?
Mismatch repair (GO:0006298) is a biological process that corrects errors in which an incorrect base, which cannot form hydrogen bonds with the corresponding base in the parent strand, is incorporated into the daughter strand. The MMR system promotes genomic fidelity by repairing base-base mismatches, insertion-deletion loops, and heterologies generated during DNA replication and recombination.
Why Is mismatch repair Important in Cell Biology?
Mismatch repair is critical for maintaining genomic integrity, and its dysfunction is directly linked to cancer predisposition and progression. MMR deficiency leads to microsatellite instability (MSI), a hallmark of Lynch syndrome and approximately 15% of sporadic colorectal cancers. Beyond cancer, MMR proteins participate in DNA damage responses and have been implicated in neurodegenerative disorders such as Huntington's disease. Understanding MMR mechanisms is essential for developing diagnostic biomarkers and therapeutic strategies, including immune checkpoint inhibitors that show efficacy in MMR-deficient tumors.
• MMR prevents mutations by correcting replication errors, reducing mutation rates by 100-1000 fold.
• MMR deficiency causes microsatellite instability (MSI), a key diagnostic marker for Lynch syndrome and sporadic cancers.
• MMR status predicts response to immune checkpoint inhibitors in solid tumors.
• Germline mutations in MMR genes (MLH1, MSH2, MSH6, PMS2) cause Lynch syndrome, the most common hereditary colorectal cancer syndrome.
• MMR proteins have non-canonical roles in DNA damage signaling and apoptosis.
• MMR dysfunction is implicated in Huntington's disease pathogenesis through somatic repeat expansion.
• MMR is involved in homeologous recombination, affecting speciation and genome evolution.
• MMR gene variants are found in sporadic solid cancers, influencing tumor mutational burden.
• MMR is a target for synthetic lethal strategies in cancer therapy.
• CRISPR screens have identified MMR genes as modulators of drug resistance and immunotherapy response.
What Happens During mismatch repair?
Mismatch Recognition by MutS Homologs
In simple terms: The MMR system first detects the mistake in the DNA.
The process begins when MutS homolog complexes (MSH2-MSH6 or MSH2-MSH3) recognize base-base mismatches or insertion-deletion loops. MSH2-MSH6 primarily recognizes single base mismatches and small loops, while MSH2-MSH3 recognizes larger loops. This recognition step is ATP-dependent and induces a conformational change that recruits downstream factors.
Recruitment of MutL Homologs and Strand Discrimination
In simple terms: Helper proteins are called in to determine which strand has the error.
MutL homolog complexes (MLH1-PMS2, MLH1-PMS1, or MLH1-MLH3) are recruited to the mismatch-bound MutS complex. These complexes coordinate strand discrimination, which in eukaryotes is directed by nicks or gaps in the newly synthesized strand. PCNA and RPA are also involved in strand discrimination and stabilization.
Excision of the Error-Containing Strand
In simple terms: The incorrect piece of DNA is cut out.
Exonuclease 1 (EXO1) is activated by MutL complexes and excises the error-containing strand from the strand break to beyond the mismatch. This excision step is ATP-dependent and requires the coordinated action of MutS, MutL, and EXO1. The resulting gap is stabilized by RPA.
Resynthesis and Ligation
In simple terms: The gap is filled in with the correct DNA sequence.
DNA polymerase delta resynthesizes the excised region using the parental strand as a template, and DNA ligase I seals the remaining nick. This step restores the correct sequence and completes the repair process. The entire pathway is highly conserved from bacteria to humans.
Non-Canonical Functions and Damage Signaling
In simple terms: MMR proteins also have other jobs beyond fixing replication errors.
Beyond canonical repair, MMR proteins participate in DNA damage responses, including cell cycle arrest and apoptosis following certain types of DNA damage. These non-canonical functions are mediated by MutS and MutL complexes and can influence chemosensitivity and immunotherapy responses. MMR deficiency also leads to a mutator phenotype and microsatellite instability.
Key Genes Involved in GO:0006298 mismatch repair
The following genes encode core and accessory proteins that execute mismatch repair in human cells.
| Gene | Major Role | Research Relevance |
|---|---|---|
| MSH2 | Core mismatch recognition; forms heterodimers with MSH6 or MSH3 | Lynch syndrome; MSI biomarker; immunotherapy response |
| MSH6 | Recognizes single base mismatches and small loops | Lynch syndrome; mutational signatures |
| MSH3 | Recognizes larger insertion-deletion loops | Cancer predisposition; repeat instability |
| MLH1 | Core MutL homolog; coordinates excision and strand discrimination | Lynch syndrome; most commonly mutated MMR gene |
| PMS2 | Forms heterodimer with MLH1; endonuclease activity | Lynch syndrome; immunotherapy biomarker |
| PMS1 | MutL homolog; forms heterodimer with MLH1 | Cancer risk modifier; MMR function |
| MLH3 | MutL homolog; involved in meiosis and repair | Repeat instability; cancer |
| EXO1 | Exonuclease that excises error-containing strand | MMR efficiency; cancer risk |
| PCNA | Sliding clamp; aids strand discrimination and resynthesis | MMR coordination; DNA replication |
| RPA | Single-stranded DNA binding; stabilizes excision gap | MMR intermediate stabilization |
| POLD1 | DNA polymerase delta; resynthesizes excised strand | MMR completion; cancer |
| LIG1 | DNA ligase I; seals nick after resynthesis | MMR completion |
| RFC | Clamp loader; loads PCNA | MMR and replication |
| HMGB1 | Chromatin protein; modulates MMR | MMR regulation |
| MBD4 | Mismatch-specific glycosylase; alternative repair | CpG mismatch repair |
| TDG | Thymine DNA glycosylase; alternative repair | G:T mismatch repair |
| ATR | DNA damage response kinase; interacts with MMR | Non-canonical MMR signaling |
| TP53 | Tumor suppressor; mutated in MMR-deficient cancers | Cancer progression |
How Is mismatch repair Regulated?
Mismatch repair is regulated at multiple levels. Transcription of MMR genes can be influenced by epigenetic modifications, including promoter methylation of MLH1, which is a common mechanism of MMR deficiency in sporadic cancers. At the protein level, MMR activity is modulated by post-translational modifications such as phosphorylation and ubiquitination, and by interactions with PCNA and RPA. Additionally, MMR proteins participate in DNA damage signaling pathways that can be regulated by ATR and ATM kinases. Non-canonical functions of MMR in neurodegeneration may involve regulation by stress response pathways.
mismatch repair and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| MLH1 | Lynch syndrome; sporadic colorectal cancer with MSI | MLH1 knockout HCT116 cells; knock-in of patient mutations |
| MSH2 | Lynch syndrome; endometrial cancer | MSH2 knockout HEK293T; point mutation knock-in |
| MSH6 | Lynch syndrome; colorectal cancer | MSH6 knockout organoids; overexpression |
| PMS2 | Lynch syndrome; immunotherapy response | PMS2 knockout mouse models; knock-in |
| MSH3 | Huntington's disease; repeat expansion | MSH3 knockout striatal cells; overexpression |
Mismatch Repair Deficiency in Cancer
MMR deficiency (dMMR) leads to microsatellite instability (MSI) and a hypermutator phenotype, which is a hallmark of Lynch syndrome and a subset of sporadic cancers, including colorectal, endometrial, and gastric cancers. dMMR tumors often have high tumor mutational burden and respond well to immune checkpoint inhibitors. Germline mutations in MLH1, MSH2, MSH6, or PMS2 cause Lynch syndrome, while somatic MLH1 promoter methylation is a common cause of sporadic dMMR.
Mismatch Repair and Neurodegeneration
MMR proteins have been implicated in Huntington's disease, where they contribute to somatic CAG repeat expansion. MSH2, MSH3, MLH1, and PMS2 are involved in the expansion process, and their inhibition reduces repeat instability in model systems. This highlights non-canonical roles of MMR in neurodegenerative disorders.
Mismatch Repair in Homeologous Recombination
MMR proteins also play a role in homeologous recombination, where they prevent recombination between divergent sequences. This function is important for genome stability and speciation, and its disruption can lead to chromosomal rearrangements.
From mismatch repair-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of MLH1 cause MMR deficiency? | MLH1 knockout in HCT116 or HEK293T cells |
| Does a specific MSH2 variant impair mismatch recognition? | Point mutation knock-in of MSH2 variant in MMR-proficient cells |
| Can overexpression of MSH6 rescue MMR? | MSH6 overexpression in MSH6-null cells |
| What is the role of PMS2 in immunotherapy response? | PMS2 knockout in cancer cell lines followed by checkpoint inhibitor treatment |
| How does MSH3 affect CAG repeat expansion? | MSH3 knockout in Huntington's disease patient-derived cells |
| Can tagged MSH2 be used to track MMR complexes? | Knock-in of fluorescent tag at MSH2 locus |
How to Study the mismatch repair Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout screens | Gene essentiality and drug response | Identify MMR genes affecting immunotherapy |
| Microsatellite instability PCR | MSI status | Diagnose Lynch syndrome and validate models |
| Whole-exome sequencing | Mutational burden and signatures | Characterize MMR-deficient tumors |
| In vitro MMR assay | Repair activity | Validate MMR gene variants |
| Immunohistochemistry | MMR protein expression | Clinical diagnosis of dMMR |
| RNA-seq | Gene expression changes | Assess MMR gene regulation |
| Proteomics | Protein interactions and modifications | Study MMR complex assembly |
| CRISPR knock-in | Tagged protein localization | Track MMR dynamics in live cells |
CRISPR Screens for MMR Genes
Genome-wide CRISPR knockout screens have identified MMR genes as key modulators of drug resistance and immunotherapy response. These screens use lentiviral sgRNA libraries to systematically knock out genes and assess phenotypes such as microsatellite instability or survival under treatment.
Microsatellite Instability Assays
MSI is assessed by PCR amplification of microsatellite loci followed by capillary electrophoresis. This method is used to diagnose MMR deficiency in tumors and to validate MMR gene knockouts in cell models.
Next-Generation Sequencing for Mutational Signatures
Whole-exome or whole-genome sequencing can reveal mutational signatures associated with MMR deficiency, such as small indels at mononucleotide repeats. This approach is used to characterize MMR-deficient tumors and cell models.
Functional MMR Assays
In vitro MMR assays using cell extracts and heteroduplex DNA substrates measure repair activity. These assays can be used to validate the functional impact of MMR gene variants and to test the efficacy of CRISPR-engineered models.
How CRISPR Can Be Used to Study GO:0006298 mismatch repair
Knockout
CRISPR knockout of MMR genes such as MLH1, MSH2, or PMS2 creates MMR-deficient cell models that exhibit microsatellite instability and a hypermutator phenotype. These models are used to study cancer initiation, drug resistance, and immunotherapy response.
Point Mutation
Point mutation knock-in allows the introduction of specific patient-derived variants (e.g., MSH2 missense mutations) to assess their functional impact on MMR activity. This approach helps distinguish pathogenic from benign variants.
Knock-in
Knock-in of fluorescent or epitope tags at endogenous MMR gene loci enables real-time tracking of protein localization and complex assembly. This is useful for studying MMR dynamics and non-canonical functions.
Overexpression
Overexpression of MMR genes (e.g., MSH6 or PMS2) in deficient cells can rescue MMR activity and reverse MSI. This approach is used to confirm gene function and to study dosage effects.
How EDITGENE Supports mismatch repair Research
Researchers studying mismatch repair-related genes often need to determine whether a candidate gene is causally involved in MMR deficiency, cancer predisposition, or therapy response. EDITGENE provides a comprehensive suite of CRISPR-based services to create precise cell models for functional validation.
Contact EDITGENE today to design your custom CRISPR model for mismatch repair research.
Frequently Asked Questions About mismatch repair
What is mismatch repair (GO:0006298)?
Mismatch repair is a biological process that corrects base-base mismatches and insertion-deletion loops generated during DNA replication and recombination, promoting genomic fidelity.
What genes are involved in mismatch repair?
Key genes include MSH2, MSH3, MSH6, MLH1, PMS1, PMS2, MLH3, EXO1, PCNA, RPA, POLD1, and LIG1.
How does mismatch repair deficiency cause cancer?
MMR deficiency leads to microsatellite instability and a hypermutator phenotype, increasing mutation rates and cancer predisposition, as seen in Lynch syndrome.
What is microsatellite instability (MSI)?
MSI is a condition of genetic hypermutability caused by MMR deficiency, characterized by length changes in microsatellite repeats.
Which cancers are associated with mismatch repair deficiency?
Colorectal, endometrial, gastric, ovarian, and other solid cancers can be MMR-deficient.
How is mismatch repair tested in the lab?
Common methods include immunohistochemistry for MMR proteins, PCR for MSI, and next-generation sequencing for mutational signatures.
What are the non-canonical functions of mismatch repair?
MMR proteins also participate in DNA damage signaling, apoptosis, and neurodegeneration, independent of their repair role.
Can CRISPR be used to study mismatch repair?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are widely used to dissect MMR gene function.
What is the role of MSH2 in mismatch repair?
MSH2 forms heterodimers with MSH6 or MSH3 to recognize mismatches and initiate repair.
How does mismatch repair influence immunotherapy response?
MMR-deficient tumors have high mutational burden and respond better to immune checkpoint inhibitors.
Conclusion
Mismatch repair (GO:0006298) is a fundamental biological process that safeguards genomic integrity by correcting replication errors. Its dysfunction is causally linked to cancer predisposition, microsatellite instability, and emerging roles in neurodegeneration. Understanding the molecular mechanisms and regulatory networks of MMR is essential for developing diagnostic biomarkers and therapeutic strategies. CRISPR-based models provide powerful tools to dissect MMR gene function and to translate these insights into clinical applications.
References
- 1. Olave MC et al.. 2022. Mismatch repair deficiency: The what, how and why it is important.. Genes Chromosomes Cancer 61(6):314-321 PMID: 34837268
- 2. Fishel R. 2015. Mismatch repair.. J Biol Chem 290(44):26395-403 PMID: 26354434
- 3. Ijsselsteijn R et al.. 2020. DNA mismatch repair-dependent DNA damage responses and cancer.. DNA Repair (Amst) 93:102923 PMID: 33087264
- 4. Miller CJ et al.. 2022. Mismatch repair is a double-edged sword in the battle against microsatellite instability.. Expert Rev Mol Med 24:e32 PMID: 36059110
- 5. Caja F et al.. 2020. DNA Mismatch Repair Gene Variants in Sporadic Solid Cancers.. Int J Mol Sci 21(15) PMID: 32756484
- 6. Iyer RR et al.. 2021. DNA Mismatch Repair and its Role in Huntington's Disease.. J Huntingtons Dis 10(1):75-94 PMID: 33579865
- 7. Tham KC et al.. 2016. Mismatch repair and homeologous recombination.. DNA Repair (Amst) 38:75-83 PMID: 26739221
- 8. Dąbrowska A et al.. 2025. Mismatch Repair Deficiency and the Role of Non-Canonical Functions in Cancer: Diagnosis and Therapeutic Implications.. Int J Mol Sci 26(19) PMID: 41096581
